Research news
Scientists in the UK have uncovered evidence that simple vision tests can predict who will develop Parkinson's dementia. And the evidence shows that a loss of wiring in the brain may be the cause.
We’ve partnered with Alzheimer’s Society and University College London Hospitals (UCLH) Biomedical Research Centre. Together, we’ve developed a new resource to help lab-based researchers with patient and public involvement (PPI).
Parkinson’s UK is joining forces with US charity The Michael J. Fox Foundation and biopharma company Neurolixis to fund a £1.5m clinical trial of an exciting new drug to combat dyskinesia in people with Parkinson’s.
We're funding a new research study into a possible treatment for hallucinations in Parkinson's.
Researchers in the US have uncovered a link between long-term exposure to pollution and deterioration in health conditions. This includes Parkinson's and Alzheimer's.
Parkinson's UK funded research suggests it may be possible to prevent the formation of protein clumps that cause problems in Parkinson's by using microscopic tweezers that pull apart the proteins. This could pave the way for a therapy that could slow or stop the progression of the condition.
Simvastatin is a drug already used to lower cholesterol, and prevent heart attacks and strokes. Initial results from a major clinical trial show it doesn't have potential to slow the progression of Parkinson's as previously hoped.
Researchers in Portugal have discovered that the content of dreams, particularly those with negative emotions, may predict long-term cognitive decline in people with Parkinson’s.
An international team of researchers have uncovered a biological link that may account for why those with diabetes have a higher risk of developing Parkinson’s.
We’re investing a further £1 million to drive forward drugs that target energy-producing mitochondria to slow the loss of brain cells in Parkinson's.